Zimmer Biomet Advances in GenAI Technology With RevelAi
Zimmer Biomet (NYSE: ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence-powered engagement solutions, which, in turn, should help the advancement of value-based orthopedic care and health equity.
The partnership is aimed at making orthopedic care more accessible to underserved and vulnerable populations as well as helping clinicians achieve maximum value-based outcomes. This will, in a way, increase Zimmer Biomet’s customer reach by helping the company to get involved in social causes and cater to clinician problems in a better way.
More on the Partnership
Throughout this agreement, Zimmer Biomet will commercialize RevelAi’s patient care-management platform, care team dashboard for providers and other future products or services.
RevelAi is optimistic about the deal and noted that using AI with Zimmer Biomet’s innovative technology is a perfect way to address socio-demographic inequality to get equal value-based outcomes. RevelAi’s AI-enabled asynchronous care model provides personalized, timely and effective patient care while reducing clinician burnout. The collaboration is a significant move to provide the necessary aid that every patient deserves.
About RevelAi Health
RevelAi Health is a software-as-a-service health technology company specializing in unique generative AI population health solutions. It helps healthcare providers to adopt value-based care with the use of a large language model. The company also meets the Centers for Medicare & Medicaid Services requirements, including Patient Reported Outcome measures …
Full story available on Benzinga.com